Evidence map›Paper›PMID 39247343›Full record

ReviewHeliyon2024

Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action.

Yutong Liang, Xiaoxiao Quan, Ruolan Gu, Zhiyun Meng, Hui Gan, Zhuona Wu, Yunbo Sun, Huajie Pan, Peng Han, Shuchen Liu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yutong LiangBeijing Institute of Radiation Medicine, Beijing, China.
Xiaoxiao QuanBeijing Institute of Radiation Medicine, Beijing, China.
Ruolan GuBeijing Institute of Radiation Medicine, Beijing, China.
Zhiyun MengBeijing Institute of Radiation Medicine, Beijing, China.
Hui GanBeijing Institute of Radiation Medicine, Beijing, China.
Zhuona WuBeijing Institute of Radiation Medicine, Beijing, China.
Yunbo SunBeijing Institute of Radiation Medicine, Beijing, China.
Huajie PanGeneral Internal Medicine Department, Jingnan Medical District, PLA General Hospital, Beijing, China.
Peng HanBeijing Institute of Radiation Medicine, Beijing, China.
Shuchen LiuBeijing Institute of Radiation Medicine, Beijing, China.
Guifang DouBeijing Institute of Radiation Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the coronavirus disease-2019 outbreak caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an ongoing need to seek drugs that target COVID-19. First off, novel drugs have a long development cycle, high investment cost, and are high risk. Second, novel drugs must be evaluated for activity, efficacy, safety, and metabolic performance, contributing to the development cycle, investment cost, and risk. We searched the Cochrane COVID-19 Study Register (including PubMed, Embase, CENTRAL, ClinicalTrials.gov, WHO ICTRP, and medRxiv), Web of Science (Science Citation Index, Emerging Citation Index), and WHO COVID-19 Coronaviral Disease Global Literature to identify completed and ongoing studies as of February 20, 2024. We evaluated the pharmacological effects,

Indexed as

Clinical trialsDrug repositioningPharmacological effectsSevere acute respiratory syndrome coronavirus type 2

Identifiers

PMID39247343
PMCPMC11379597

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.